First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

OBJECTIVES: Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting. DESIGN: Retrospective, observational multicentre study. SETTING: We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzler, Katja, Mross, Peter Michael, Rosenow, Felix, Schubert-Bast, Susanne, Willems, Laurent Maximilian, Zahnert, Felix, Immisch, Ilka, Fuest, Sven, von Podewils, Felix, Kunz, Rhina, Hirsch, Martin, Mueller, Tamara, Marquetand, Justus, Winter, Yaroslav, Langenbruch, Lisa, Cicanic, Michal, Beyenburg, Stefan, Strzelczyk, Adam, Knake, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858140/
https://www.ncbi.nlm.nih.gov/pubmed/31690606
http://dx.doi.org/10.1136/bmjopen-2019-030746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858140/
https://www.ncbi.nlm.nih.gov/pubmed/31690606
http://dx.doi.org/10.1136/bmjopen-2019-030746

Ejemplares similares